AMERICANTHINKER - The Dumb, Arrogant Liars Who Are Also Journalists
Image via Pixnio . Pixnio By J.B. Shurk Fauci’s COVID lies expose corporate news as propaganda.
AMERICANTHINKER - What It’s Really Like to Deal with Iran
Image: Chickenonline via Pixabay , Pixabay License . Chickenonline By Chris J. Krisinger We’ve been doing this same dance for decades.
AMERICANTHINKER - Can Homeowners Save New York State from Socialism?
Famartin By Linda R. Killian In November, the suburbs of New York City will be the pivotal arena for whether the Democratic Socialists of America cement their takeover of the entire state from their New York City stronghold.
AMERICANTHINKER - How Postcolonialism is Nazi Adjacent
Perchance AI By Christopher Chantrill Every political movement is the story of the mystical origin of a people, and prophesies its heroic journey from the darkness of subjection into the glorious light of ascendance, the Promised Land of political dominance.
AMERICANTHINKER - Whatever Happened to Ending 'Endless Wars'?
chatgpt By Brian C. Joondeph Five months into the Iran conflict, supporters are asking whether America First still means fewer wars.
NYTIMES (Evan Gorelick) - Michigan Looks Left
We’re sizing up tomorrow’s primary contest.
NYTIMES (Aaron Boxerman and Sanam Mahoozi) - Iran Says No Current Talks With U.S. After Trump Cites Progress on the Strait of Hormuz
President Trump cited progress in the negotiations when canceling a threatened attack on Iran over the weekend. Iran said there were no current talks with the United States.
NYTIMES (Tracy Mumford, Will Jarvis, Margaret Kadifa, Jake Lucas, Ian Stewart and Ben Hubbard) - New Limits on Trump’s I.R.S. Deal, and Prosecutors Say Reflecting Pool Work Was ‘Botched’
Plus, why college jerseys suddenly have corporate logos.
NPR (Will Stone) - What would it take to get peptides on the shelf?
An FDA advisory panel recently voted to green-light some popular peptides. The decision brought enormous attention to the market for these products — and concerns about the unregulated supply.
An FDA advisory panel recently voted to green-light some popular peptides. The decision brought enormous attention to the market for these products — and concerns about the unregulated supply.Open